Ribociclib plus letrozole in premenopausal patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial

被引：0

作者：

Razeq, Hikmat Abdel ^{[1
]}

Cottu, Paul ^{[2
]}

Ring, Alistair ^{[3
]}

De laurentiis, Michelino ^{[4
]}

Lu, Janice ^{[5
]}

Azim, Hamdy ^{[6
]}

Zamagni, Claudio ^{[7
]}

Zhou, Katie ^{[8
]}

Wu, Jiwen ^{[8
]}

Menon-Singh, Lakshmi ^{[8
]}

Martin, Miguel ^{[9
]}

机构：

[1] King Hussein Canc Ctr, Amman, Jordan

[2] Curie Inst, Paris, France

[3] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[4] Natl Canc Inst Pascale Fdn, Naples, Italy

[5] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[6] Cairo Univ, Cairo, Egypt

[7] Bologna Univ Hosp, St Orsola Malpighi Polyclin, Bologna, Italy

[8] Novartis Pharmaceut, E Hanover, NJ USA

[9] Gregorio Maranon Gen Univ Hosp, Madrid, Spain

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS10-10

引用

页数：1